Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
J.Molner ASOTSE:MOLNR 40 Pretax Margin % is 258.82% as of Dec. 2025. GuruFocus rates OTSE:MOLNR with a GF Score™ of 40/100 and a GF Value™ of €19.63 (Fairly Valued). The stock has 7 warning signs investors should review. Among 958 Drug Manufacturers companies, J.Molner AS ranks better than 60.86% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. J.Molner AS's Pre-Tax Income for the
six
months ended in Dec. 2025 was €1.54 Mil. J.Molner AS's Revenue for the
six
months ended in Dec. 2025 was €0.60 Mil. Therefore, J.Molner AS's pretax margin for the quarter that ended in Dec. 2025 was 258.82%.
The historical rank and industry rank for J.Molner AS's Pretax Margin % or its related term are showing as below:
OTSE:MOLNR'
s Pretax Margin % Range Over the Past 10 Years
Min: -322.92 Med: -106.27 Max: 11.51
Current: 11.17
OTSE:MOLNR's Pretax Margin % is ranked better than 60.86% of 958
companies
in the Drug Manufacturers industry
Industry Median: 7.535
vs OTSE:MOLNR: 11.17
J.Molner AS (OTSE:MOLNR) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
J.Molner AS Pretax Margin % Related Terms
J.Molner AS Pretax Margin % Historical Data
* Premium members only.
The historical data trend for J.Molner AS's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OTSE:MOLNR vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
J.Molner AS Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where J.Molner AS's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
J.Molner AS (OTSE:MOLNR) has a Pretax Margin % of 258.82% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on J.Molner AS and its competitors. According to the industry distribution chart, J.Molner AS ranks #375 out of 958 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is J.Molner AS's Pretax Margin % too high?
J.Molner AS's current Pretax Margin % is 258.82%. The Drug Manufacturers industry median Pretax Margin % is 7.54. J.Molner AS's value of 258.82% is 3334.9% above this industry median. Based on the distribution chart, J.Molner AS ranks #375 out of 958 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, J.Molner AS has a GF Score™ of 40/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does J.Molner AS's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, J.Molner AS ranks #375 out of 958 companies for Pretax Margin %. This puts J.Molner AS in the upper half of its industry. The industry median Pretax Margin % is 7.54. J.Molner AS's value of 258.82% is 3334.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.54, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. J.Molner AS's current Pretax Margin % of 258.82% is 3334.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on J.Molner AS and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. J.Molner AS's current Pretax Margin % is 258.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is J.Molner AS stock overvalued right now?
Based on GuruFocus' analysis, J.Molner AS (OTSE:MOLNR) is currently considered Fairly Valued. The stock's GF Value™ is €19.63, compared to a current price of €18.90 — trading 3.7% below its estimated fair value. The current Pretax Margin % is 258.82% and 3334.9% above the Drug Manufacturers industry median of 7.54. J.Molner AS's overall GF Score™ is 40/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For J.Molner AS (OTSE:MOLNR), the current Pretax Margin % is 258.82% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?
Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued.
The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.63.
GuruFocus considers J.Molner AS to be Fairly Valued.
Key valuation signals for OTSE:MOLNR:
Pretax Margin %: 258.82%
GF Value™: €19.63 vs. price of €18.90 (3.7% below fair value)
Industry Position: 3334.9% above the Drug Manufacturers median (#375 of 958)
No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score
Get the complete analysis for OTSE:MOLNR
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTSE:MOLNR has been successfully added to your 
